About Us
Who we are and what we do.
Neuroene Therapeutics was formed after our co-founders discovered a new class of compounds to improve mitochondrial health in multiple animal models of difficult-to-treat neurological diseases.
Our long-term objective is to develop our mitochondrial modulator drug discovery platform to identify clinical candidates for diseases of underlying mitochondrial dysfunction. Neuroene Therapeutics’ portfolio includes issued and pending patents covering hundreds of analogs aimed at the treatment of numerous disease indications and the corresponding methods.
Our Team
Sherine Chan, Ph.D.
Co-Founder and CEO
Dr. Chan is a mitochondrial biologist with a Ph.D. in Clinical Biochemistry from the University of Western Australia. She has extensive experience in in vitro and in vivo drug discovery and toxicity studies.
C. James Chou, Ph.D.
Co-Founder
Dr. Chou is a medicinal chemist with a Ph.D. in Chemistry from the University of Washington. He has extensive experience in medicinal chemistry and has a drug in clinical trials for a rare mitochondrial disease known as Friedreich’s Ataxia.
Advisors
Karen Wilcox, Ph.D.
Director, Anticonvulsant Drug Development Program, University of Utah
Karen Lackey
Global Head of Integrated Drug Discovery, Evotec
Justin Yang, MBA
Alliance Management, former Director
BARDA DRIVe, Founder of BARDA Ventures
John Schreiber, M.D.
Director, Epilepsy Genetics Program at Children’s National Hospital
Russell Saneto, D.O., Ph.D.
Pediatric Neurologist, Seattle Children’s Hospital
Bruce Cohen, M.D.
Director, NeuroDevelopmental Science Center, Akron Children’s Hospital
Krista Spiller, Ph.D.
Project Leader, Neuroscience Discovery,
Janssen R&D